COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04365309

Cai Yue

Not reported

2020-04-28

Recruiting

RCT

Randomized

Parallel

Open label

single-center

Treatment

inclusion criteria: the patient volunteered to participate in the study, approved the aspirin treatment, and was willing to randomly accept one of the aspirin treatment regimens, and provided written informed consent, subject is required to meet one of the following criteria for confirmation of a novel coronavirus infection with pneumonia: 1.the detection of novel coronavirus nucleic acid is positive in respiratory or blood specimens by real-time -pcr, 2. virus gene sequencing of respiratory or blood specimen is highly homologous with known novel coronavirus, chest image confirmed pulmonary involvement; fever: ≥36.7℃ under the armpit, ≥38.0℃ in the oral cavity or ≥38.6℃ in the rectum and eardrum; • respiratory frequency ≥24 times/min or at least one cough; onset time ≤14 days; agree not to participate in another study until completion of the 14-day study; if you need to withdraw from this study; the subjects had not taken aspirin for nearly one month prior to the screening period. can follow the study or follow up procedure. -

women who have recently been pregnant or breast-feeding. having a history of active gastrointestinal bleeding in the past 3 months. blood routine examination showed that the platelet count was < 30×109/l. patients with coagulation disorders. unable to understand the potential risks and benefits of the study, and unable to follow up the evaluation as required. having no capacity for civil conduct. a history of drug or alcohol abuse. allergic to aspirin. influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia, organized pneumonia, etc. patients with cardiac stent placement (< 1 year). any more complex medical problems that may interfere with research behavior or lead to increased risk, such as malignant tumors, blood diseases, liver diseases, aids, viral hepatitis, etc.

2

Xijing Hospital

18

85

China

Moderate/severe disease at enrollment

4: Moderate/severe disease at enrollment

128

clinical recovery time (TTCR);the time of SARS-CoV2 overcasting

None

Phase 2/Phase 3

[{"arm_notes": "", "treatment_id": 129, "treatment_name": "Aspirin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]